BioSpace News Archive

NJ Biopharmaceuticals LLC welcomed the appointments of Ilan Kaufthal as Senior Advisor, and Ronald Gold , Steven Klosk , and Chetan Jain to its Board of Directors.

Millar, Inc., a leader in the field of high-fidelity, MEMS based pressure catheter technology and Schwarzer Cardiotek a leader in the field of Electrophysiology measurement systems, are pleased to announce their strategic partnership to promote the direct connection between the Millar Mikro-Cath and the EP-Tracer recording system.

Opiant Pharmaceuticals, Inc. announced that members of the company’s senior management team will participate in the following virtual investor conferences

Codexis, Inc. announced the Company received new purchase orders with an aggregate total value of approximately $15 million for the 2021 supply of a proprietary high performance enzyme used to manufacture a critical intermediate for an Active Pharmaceutical Ingredient in a therapeutic drug for an undisclosed global pharmaceutical company.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced positive topline results from the pivotal Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will relocate both its corporate headquarters and the Personalis Clinical Laboratory from Menlo Park to 6600 Dumbarton Circle in Fremont.

Bayer, a leader in women’s healthcare, today announced the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its market leading1 intrauterine device (IUD) Mirena®.

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s tislelizumab in patients with advanced triple negative breast cancer (“TNBC”) or advanced endometrial cancer (“EC”) in the U.S. The first patient was dosed on August 24, 2021.

Rise in consumption of liquid nutritional supplements, increase in incidence of chronic diseases, and healthy aging & proactive consumption of nutritional interventions are anticipated to drive the global liquid dietary supplements market from 2021 to 2031.

The increasing adoption of capsule formulations in the rising geriatric population is bolstering the empty capsules market.